Drug Trial Radar · NCT06023602
Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone(GnRH)Antagonist Protocol in Women Undergoing IVF
Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,338
Planned (sponsor's estimate)
Start
Feb 27, 2024
Primary completion
Dec 1, 2025
Study completion Dec 1, 2025
Sponsor
- Lead sponsor
- Northwest Women's and Children's Hospital, Xi'an, ShaanxiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 5, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 42 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare the clinical outcomes using different cetrorelix acetate in the context of a GnRH antagonist protocol for ovarian stimulation in women undergoing IVF or intracytoplasmic sperm injection(ICSI) treatment.The main question it aims to answer is whether the generic cetrorelix acetate is non-inferior to the reference product in the GnRH antagonist based protocol for women undergoing IVF. Ovarian stimulation was achieved by several types of follicle-stimulating hormone(FSH) or by FSH combined with luteinizing hormone activity. Daily dose of generic cetrorelix acetate (0.25 mg SC) or original cetrorelix acetate (0.25 mg SC) will be administered when the lead follicle was 14 mm. When more than two follicles reached 17 mm, oocyte maturation was triggered with 250 mcg of recombinant human chorionic gonadotropin.
Conditions
- Infertility
Interventions
Generic cetrorelix acetateDrug
Generic cetrorelix acetate (0.25 mg SC)
Reference cetrorelix acetateDrug
reference cetrorelix acetate (0.25 mg SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative live birth rateTime frame: Through study completion, an average of 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
He Cai
Xi'an, None Selected, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.